Will the $74bn Celgene deal be done before the market slows?

Will the $74bn Celgene deal be  done before the market slows?

Deal would be largest pharmaceutical merger on record

Bristol-Myers Squibb has agreed to acquire Celgene Corp in a $74 billion deal that will unite two drug-makers battling for advantage in a crowded market for innovative cancer treatments.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events
  • Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
  • Access to The Business Post's extensive archive​

Related Articles

More from The Business Post